Pharsight

Omlonti is owned by Santen.

Omlonti contains Omidenepag Isopropyl.

Omlonti has a total of 9 drug patents out of which 0 drug patents have expired.

Omlonti was authorised for market use on 22 September, 2022.

Omlonti is available in solution;ophthalmic dosage forms.

Omlonti can be used as method of treating open-angle glaucoma or ocular hypertension in patients.

Drug patent challenges can be filed against Omlonti from 2026-09-22.

The generics of Omlonti are possible to be released after 10 June, 2035.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648097	SANTEN	Pyridylaminoacetic acid compound	Oct, 2029 (6 years from now)
US10774072	SANTEN	Crystal of N-substituted sulfonamide compound	Jun, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685986	SANTEN	Medical composition for treatment or prophylaxis of glaucoma	Oct, 2029 (6 years from now)
US10765750	SANTEN	Pharmaceutical composition containing pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
US11197849	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
US9415038	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
USRE48183	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
US10702511	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)
US10179127	SANTEN	Pharmaceutical formulations comprising a pyridylaminoacetic acid compound	Jan, 2035 (11 years from now)